Radiology Case Reports (Feb 2023)

Cerebellar infarction risk in a mild COVID-19 case

  • Antigona Kabashi, MD, PhD,
  • Henri Fero, MD,
  • Artiona Gjini, MD,
  • Diana Dhimitri, MD,
  • Mimoza Spahiu, MD,
  • Fjolla Hyseni, MD, PhD,
  • Edlira Harizi, MD,
  • Kledisa Shemsi, MD,
  • Valon Vokshi, MD,
  • Arlind Decka, MD,
  • Asm al Amin, MD,
  • Ahm Ataullah, MD,
  • Livia Capi, MD,
  • Sepideh Jahanian, MD,
  • Fareeha Nasir, MD,
  • Ivan N. Ayala, MD,
  • Juna Musa, MD, MS,
  • Jeton Shatri, MD, PhD,
  • Kreshnike Dedushi, MD, PhD,
  • Florim Leniqi, MD,
  • Guri Hyseni, MD

Journal volume & issue
Vol. 18, no. 2
pp. 651 – 656

Abstract

Read online

Thrombotic events in SARS-COV-2 disease patients are frequent, especially in patients with comorbidities such as heart failure, hypertension, cancer, diabetes mellitus, kidney failure, vascular disease, and other pulmonary illnesses. In severe cases, in particular those of hospitalized patients with other comorbidities, the development of thrombotic events in spite of anticoagulation therapy has been observed. The main thrombotic events are pulmonary thromboembolism, cerebral ischemic stroke, and peripheral artery thrombosis. Despite the severity of SARS-COV-2 disease, some patients with the aforementioned comorbidities develop thrombotic events regardless of the severity of their SARS-COV-2 infection. In this setting, the cerebellum makes no exception as an uncommon, but still possible target for thrombotic events.

Keywords